Xeomin and Botox are both FDA-approved for upper-limb spasticity; however, Botox’s FDA label shows a higher rate of respiratory infections, which might be a particular concern during the COVID-19 pandemic.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”